You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The incidence of thyroid cancer has gone up 4.5 percent annually during the past decade without a corresponding change in the mortality rate, the USPSTF noted.
More than a third of the first 10,000 patients receiving MSK-IMPACT harbored actionable mutations, and 11 percent of the first 5,000 enrolled in a clinical trial.
A CE-label expansion extends the assay's application to patients being considered for Merck's Keytruda immunotherapy as the first line of treatment.
The researchers said that they are developing a fiber probe that could generate a Bessel beam that could be inserted into arteries to obtain internal images.
The company will continue to work with Maastricht University researchers to develop genetic and epigenetic cancer diagnostics.
The Medicare contractor proposed coverage for several cancer assays, but would not cover molecular respiratory virus assays or a test for inflammatory bowel disease.
The firm manufactures tissue culture-based personalized medicine assays that assesses signaling pathways to guide oncology diagnosis and treatment.
The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.
The researchers said that their blood-based ddPCR assay could differentiate men with prostate cancer who have numerous copies of the androgen receptor gene.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
There are signs that doctors may be moving away from experimental precision therapy options in favor of immunotherapy and the chance at longer survival.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
In a survey of 132 oncologists, Medscape tracked how they are using next-generation sequencing and what they think of its clinical utility.
Researchers said that laboratories participating in BRAF proficiency testing include most of the required reporting elements "to unambiguously convey molecular results."
Israel-based Best Medical Opinion and South Korea-based Dow Biomedica/Biodiscovery will distribute Oncimmune's EarlyCDTLung cancer test in those countries.
The firm's net loss in Q1 was up about 60 percent year over year, but it reported plans to share validation data for its lung cancer test next month.
MultiGen said its test identified and confirmed the BRAF p.V600E mutation with a thousandfold increase in sensitivity compared to competing PCR-based and NGS methods.
The agency approved Novartis' Rydapt for AML patients with FLT3 mutations, who will be identified by Invivoscribe's LeukoStrat CDx.
The system being developed would enable clinical decision-making based on genetic information about cancer cells and will leverage Fronteo's AI engine called KIBIT.